Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 2
1953 1
1955 4
1956 1
1957 1
1959 1
1960 2
1961 2
1962 1
1964 1
1965 1
1966 1
1968 1
1969 1
1970 3
1971 3
1972 1
1975 1
1977 1
1979 1
1980 1
1981 3
1982 2
1984 5
1985 1
1987 1
1993 1
1996 2
1999 1
2004 1
2005 2
2006 1
2011 1
2013 1
2017 1
2018 8
2019 26
2020 24
2021 24
2022 14
2023 10
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Negrao MV, et al. Among authors: mitchell kg. J Immunother Cancer. 2021 Aug;9(8):e002891. doi: 10.1136/jitc-2021-002891. J Immunother Cancer. 2021. PMID: 34376553 Free PMC article.
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.
Sepesi B, Zhou N, William WN Jr, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Sepesi B, et al. Among authors: mitchell kg. J Thorac Cardiovasc Surg. 2022 Nov;164(5):1327-1337. doi: 10.1016/j.jtcvs.2022.01.019. Epub 2022 Jan 23. J Thorac Cardiovasc Surg. 2022. PMID: 35190177 Free PMC article. Clinical Trial.
High-volume hybridoma sequencing on the NeuroMabSeq platform enables efficient generation of recombinant monoclonal antibodies and scFvs for neuroscience research.
Mitchell KG, Gong B, Hunter SS, Burkart-Waco D, Gavira-O'Neill CE, Templeton KM, Goethel ME, Bzymek M, MacNiven LM, Murray KD, Settles ML, Froenicke L, Trimmer JS. Mitchell KG, et al. Sci Rep. 2023 Sep 27;13(1):16200. doi: 10.1038/s41598-023-43233-4. Sci Rep. 2023. PMID: 37758930 Free PMC article.
Current Surgical Indications for Non-Small-Cell Lung Cancer.
Deboever N, Mitchell KG, Feldman HA, Cascone T, Sepesi B. Deboever N, et al. Among authors: mitchell kg. Cancers (Basel). 2022 Feb 28;14(5):1263. doi: 10.3390/cancers14051263. Cancers (Basel). 2022. PMID: 35267572 Free PMC article. Review.
Response to letter to the editor.
Corsini EM, Mitchell KG, Antonoff MB. Corsini EM, et al. Among authors: mitchell kg. J Surg Oncol. 2019 Nov;120(6):1051-1052. doi: 10.1002/jso.25688. Epub 2019 Aug 26. J Surg Oncol. 2019. PMID: 31448815 No abstract available.
140 results